AOD-9604
aodaod9604
Modified HGH fragment — fat-loss focus, lipolytic. Failed obesity trials; protocol design implications.
- Half-life
- 1.5 h
- Out of system
- ~8 h
- Route
- Subcutaneous
- Level
- Intermediate
Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~8 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What AOD-9604 is used for
- Modified HGH fragment — lipolytic, fat-loss focus
- No measurable GH or IGF-1 elevation
How it's typically used
Research range: ~300 mcg subcutaneous daily (often fasted).
What to watch for
- Failed obesity trials — efficacy is modest at best
- Long-term human data is thin
- Research-only; verify sourcing/COA
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
AOD-9604: A Tracking Guide for an hGH Fragment
What AOD-9604 is, why it failed in obesity trials, and how to track fat-loss protocols if you choose to use it.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.